Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 16/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 16/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 16/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 16/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 16/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 16/20 | 0.40 |
| ▸ | GCK | P35557 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24954122 | 0.91 | GCK (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL24953728 | 0.91 | GCK (0.35) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL24953924 | 0.91 | GCK (0.35) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL24953737 | 0.91 | GCK (0.44) | GCK | |
| SCHEMBL24952962 | 0.91 | GCK (0.44) | GCK | |
| SCHEMBL24953890 | 0.86 | CCNE1 (0.46) | — | |
| SCHEMBL24953935 | 0.86 | GCK (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL24952913 | 0.86 | GCK (0.38) | GCK | |
| SCHEMBL24952914 | 0.85 | ACACB (0.34) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL24953681 | 0.84 | GCK (0.38) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029266-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | DERMIRA, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029266-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | MRGPRX2, MRGPRX1, MRGPRX4 | PSEN1 2415/4885PSEN2 1308/4885APH1B 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.